- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06044532
SKAMo-1: Characterization of the Upper Layers of Skin
Diabetes is a frequent disease characterized by chronic hyperglycemia, and its prevalence is increasing worldwide. Historically, patients with diabetes were required to monitor capillary blood glucose concentration up to several times a day through fingertip sampling.
Recently marketed devices now allow measurements of interstitial fluid blood glucose continuously, thus limiting pain associated with sampling. However, they are still invasive and have to be changed every 14 days.
Therefore, to optimize continuous glycemia monitoring while avoiding pain, discomfort, and the risk of infection, non-invasive methods are needed. Among the different strategies being developed, optical wearable sensors with specific signal processing are a promising option. The sensors detecting this optical signal will be included in a device. Yet, wearing a device may slightly modify several properties of the skin, such as its humidity and thermal regulation, and subsequently have an impact on the measured optical signal. Therefore, it is important to better understand how a device affects these characteristics to include these parameters in the future device algorithms.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Grenoble, France, 38043
- Chu Grenoble Alpes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged ≥ 18 years and ≤ 60 years
- Signed informed consent
- Person who is affiliated to a social security scheme or who is beneficiary of such a scheme
Exclusion Criteria:
- Body mass index (BMI) > 30 kg/m2
- Any acute or chronic disease with vascular impact
- Any cutaneous disease on sites implicated in the study (dorsum of the forearm)
- Allergy to one of the material used in the sham device and during the procedure of the study
- The persons mentioned in articles L1121-5 to L1121-8 of the public health code may not be included in this research
- Subject who would receive more than 4500 euros in compensation due to his or her participation in other research involving the human person in the 12 months preceding this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Skin characterization
|
At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated.
At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of skin hydration on the dorsum of the forearm after two and a half hours of wearing the sham device.
Time Frame: Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
Hydration is measured with a capacitance method, expressed as arbitrary units (dielectric value)
|
Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of skin elasticity after the wearing the sham device
Time Frame: Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
elasticity (suction method) expressed as penetration depth in mm/time
|
Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
|
Change of transepidermal water loss after the wearing the sham device
Time Frame: Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
transepidermal water loss (the density gradient of the water evaporation) expressed as the evaporation rate in g/h/m2
|
Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
|
Change of thickness of the stratum corneum after the wearing the sham device
Time Frame: Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
thickness of the stratum corneum (LC-OCT method) expressed as mm
|
Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
|
Change of skin temperature after the wearing the sham device
Time Frame: Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
skin temperature (infrared thermography) expressed as Celsius,
|
Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
|
Change of skin blood flux after the wearing the sham device
Time Frame: Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
skin blood flux (LSCI) expressed as an arbitrary unit,
|
Visit 1,Day 0, before and after two and a half hours of wearing the sham device
|
|
Change of skin hydration after skin cleaning
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
|
Change of skin elasticity after skin cleaning
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
|
Change of transepidermal water loss after skin cleaning
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
|
Change of thickness of the stratum corneum after skin cleaning
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
|
Change of skin temperature after skin cleaning
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
|
Change of skin blood flux after skin cleaning
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning
|
|
Change of skin hydration after skin sanding
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
|
Change of skin elasticity after skin sanding
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
|
Change of transepidermal water loss after skin sanding
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
|
Change of thickness of the stratum corneum after skin sanding
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
|
Change of skin temperature after skin sanding
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
|
Change of skin blood flux after skin sanding
Time Frame: Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
expressed as previously described
|
Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding
|
|
Change of skin hydration after local heating
Time Frame: Visit 2, Day 7 (+/-6 days), before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days), before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
|
Change of skin elasticity after local heating
Time Frame: Visit 2, Day 7 (+/-6 days), before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days), before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
|
Change of transepidermal water loss after local heating
Time Frame: Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
|
Change of thickness of the stratum corneum after local heating
Time Frame: Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
|
Change of skin temperature after local heating
Time Frame: Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
|
Change of skin blood flux after local heating
Time Frame: Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)
|
|
Change of skin hydration induced by oral glycemia tolerance test
Time Frame: Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
|
Change of skin elasticity induced by oral glycemia tolerance test
Time Frame: Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
|
Change of transepidermal water loss induced by oral glycemia tolerance test
Time Frame: Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
|
Change of thickness of the stratum corneum induced by oral glycemia tolerance test
Time Frame: Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
|
Change of skin temperature induced by oral glycemia tolerance test
Time Frame: Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
|
Change of skin blood flux induced by oral glycemia tolerance test
Time Frame: Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
expressed as previously described
|
Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2022-A02578-35
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)United States
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceCompletedType 2 Diabetes Mellitus | Pre DiabetesAustralia
Clinical Trials on Experimental
-
Polish Mother Memorial Hospital Research InstituteCompletedBottle Feeding | PrematurePoland
-
Finis Terrae UniversityNot yet recruitingPostoperative Pain | Respiratory ComplicationChile
-
Riphah International UniversityRecruitingAthletic Performance | Muscle StrengthPakistan
-
University of AlcalaRecruitingTo be Approved by the Ethics CommitteeSpain
-
Suleyman Demirel UniversityCompletedOsteoporosis (Senile)Turkey (Türkiye)
-
University of Illinois at ChicagoRecruiting
-
European University Miguel de CervantesHospital Clínico Universitario de ValladolidNot yet recruiting
-
Amasya UniversityCompleted
-
Le Mans UniversiteActive, not recruiting
-
Center for Health Sciences, SerbiaNot yet recruitingCognitive Deficits, Mild